Atypical hyperplasia of the breast: Cancer risk-reduction strategies
Women with atypical hyperplasia are at increased risk for breast cancer. We need to characterize that risk for patients and ensure appropriate screening and cancer risk-reduction strategies. Here, recommendations for clinical practice.
In this Article
- Dr. Samiian: How I counsel patients about their management options
- Mammography shows microcalcifications
Most women will not develop breast malignancy
As Hartmann and colleagues point out, all is not dire once a woman is diagnosed with atypical hyperplasia of the breast. In most of these women, breast cancer will not develop—and if it does develop, it may occur at an age when mortality from other causes is more likely than from breast cancer. In this respect, women with atypical hyperplasia of the breast are different from carriers of BRCA mutations. Although women with atypical hyperplasia as well as mutation carriers are both at high lifetime risk for breast cancer, breast malignancies occur at an earlier age in mutation carriers. Accordingly, as the authors of this special report advise, in general, a diagnosis of atypical hyperplasia should not be considered an indication for risk-reducing bilateral mastectomy.
Share your thoughts on this article! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.
